Deprecated: Creation of dynamic property WhitelabelOptions::$_title is deprecated in /home/grassnews/public_html/wp-content/themes/zox-news/admin/admin-page.php on line 79
DATA Communications Management Corp. Announces First Quarter Financial Results for 2019 – GrassNews
Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

DATA Communications Management Corp. Announces First Quarter Financial Results for 2019

Published

on

Reading Time: 14 minutes

HIGHLIGHTS

FIRST QUARTER 2019

  • Revenues of $78.5 million compared with $88.5 million in the prior
    year; the prior period included significantly higher volume from one
    particular customer
  • Gross margin as a percentage of revenue improved to 26.4% from 24.3%
    in the prior year comparative period
  • Reduction in selling, general & administrative expenses by $0.5
    million versus the same quarter last year
  • Adjusted EBITDA of $7.9 million, compared to $6.4 million in the prior
    year (See Table 2 and “Non-IFRS Measures” below). Excluding the
    effects of adopting IFRS 16 Leases (“IFRS 16”), Adjusted EBITDA
    was $5.4 million
  • Net loss of $0.3 million, including restructuring expenses of $1.7
    million compared to net income of $1.8 million, including
    restructuring expenses of $0.1 million in the prior comparative period
  • Adjusted net income of $1.2 million, compared to $2.1 million in the
    prior comparative period (See Table 3 and “Non-IFRS Measures” below).
    Excluding the effects of adopting IFRS 16, Adjusted net income was
    $1.7 million
  • Adopts new accounting standard IFRS 16 Leases effective January
    1, 2019

RECENT EVENTS

  • DCM announces it has entered into a significant multi-year agreement
    to provide innovative technology solutions to a large provincial
    health services network
  • Sale of loose-leaf binders and index tab business to Southwest
    Business Products Ltd (“Southwest”) and long-term supply agreement
    with Southwest
  • Strategic decision to outsource Brossard, Quebec stationery production
    and expand existing tier two supplier agreement for the provision of
    stationery

BRAMPTON, Ontario–(BUSINESS WIRE)–DATA Communications Management Corp. (TSX:DCM) (“DCM” or the “Company”),
a leading provider of marketing and business communication solutions to
companies across North America, announces its consolidated financial
results for the three months ended March 31, 2019.

“We continue to focus your Company’s efforts on providing additional
products and services to our core client base. In addition, with the
enhanced retail and consumer insight capabilities Perennial brings to
DCM, we are capturing new client business due to the innovative ideas
and exceptional executional capabilities we are presenting to clients.
Our “pitched and pending” sales pipeline is at historic highs with both
current and new clients,” said Gregory J. Cochrane, CEO.

CONTINUING THE PIVOT
DCM announced its Business Solutions Group was
recently awarded a significant multi-year agreement to provide
innovative technology solutions to a large provincial healthcare
services network as it transforms its clinical information systems to
become more integrated with enhanced automation tools. Key components to
be provided by DCM include scanners, printers, patient identification
solutions, consumables including labels, as well as ongoing support
services.

Advertisement
Stake.com

“This long-standing customer of DCM in our traditional business has
trusted DCM to consult, evaluate, recommend and execute a business
solutions platform which will dramatically modernize the way this
province delivers health care services to its customers,” said Mr.
Cochrane. “By recommending the appropriate technology and business
processes to this client, DCM is now seen as a total enterprise
solutions provider instead of a print production vendor. DCM began to
record revenue in the second quarter of 2019 under this agreement.”

DCM recently announced the sale of its loose-leaf binders and index tab
business to Southwest, which closed on May 2, 2019. The sale was made by
way of an asset purchase agreement in which certain assets were sold and
certain liabilities were assumed by Southwest in exchange for cash
proceeds to DCM. At the same time, DCM entered into a long-term supply
agreement with Southwest as a preferred vendor of binders, index tabs
and related products. DCM expects to incur restructuring costs of
approximately $0.4 million in connection with this initiative in the
second quarter of 2019 primarily related to a reduction in headcount.
This transaction aligns with DCM’s strategy to focus on products and
solutions that are critical to its top customers, and to source non-core
offerings from other leading providers where it makes strategic sense.

Consistent with this theme, in early March 2019, DCM initiated plans to
outsource its Brossard, Quebec stationery production to a long-standing
tier two supplier. DCM also expanded its pre-existing supply agreement
with this partner. Effective May 1, 2019, DCM closed the Brossard,
Quebec facility, which primarily produced stationery products including
business cards and letterhead and relocated the facility’s digital print
on demand production to other DCM sites. As a result of the Brossard
closure, DCM incurred restructuring costs of approximately $0.5 million
in the first quarter of 2019 for severance costs. While DCM does not
expect material changes in revenue or margins from this initiative, it
allows DCM to better serve its customers with a seamless offering, and
to avoid additional investment in what it sees as a declining business
segment.

In the first quarter of 2019, DCM also initiated direct and indirect
labour savings across a number of its facilities as part of its
strategic focus on improving overall profitability. DCM incurred
restructuring costs of $1.2 million in the first quarter of 2019 for
severance costs associated with this reduction of employees. Total
annualized savings from these reduced labour costs are estimated to be
$1.2 million.

EXTENSION OF BANK CREDIT FACILITY
On March 5, 2019, DCM entered
into a second amendment to its credit agreement with a Canadian
chartered bank in relation to its revolving credit facility (“Bank
Credit Facility”). Significant terms of the amendment made to the credit
facility include an extension of the maturity date to January 31, 2023,
from its original maturity date of March 31, 2020; a reduction in the
prime rate margin on advances by 15 basis points from 0.75% per annum to
0.60% per annum; the elimination of an early termination fee in the
event the credit facility is terminated or repaid prior to maturity; and
amendments related to the calculation of certain financial covenants as
a result of the adoption of IFRS 16 effective for reporting periods on
or after January 1, 2019. The amendments related to IFRS 16 include
clarification that the calculation of DCM’s fixed charge coverage ratio
under the Bank Credit Facility will be completed on a basis that
substantially has the same effect as the results prior to the adoption
of IFRS 16 whereby lease payments will also be deducted from EBITDA, in
addition to all other adjustments previously allowed per the credit
agreement. As a result, definitions of certain terms related to IFRS 16
were added to the credit agreement. DCM’s financial covenant ratio with
the bank remains unchanged. On April 29, 2019, DCM entered into a lease
agreement with the bank pursuant to a master lease agreement dated July
31, 2018 in connection with the Gallus hybrid label press which was
fully commissioned earlier in the month.

Advertisement
Stake.com

RESULTS OF OPERATIONS
All financial information in this
press release is presented in Canadian dollars and in accordance with
International Financial Reporting Standards (“IFRS”), as issued by the
International Accounting Standards Board (“IASB”).

Table 1 The following table sets out selected historical
consolidated financial information for the periods noted.
             
For the periods ended March 31, 2019 and 2018    

Jan. 1 to
Mar. 31,
2019 (1)

   

Jan. 1 to
Mar. 31,
2018

(in thousands of Canadian dollars, except share and per share
amounts, unaudited)
    $     $
Revenues 78,549 88,516
Cost of revenues     57,787       67,041  
Gross profit 20,762 21,475
Selling, general and administrative expenses 17,158 17,672
Restructuring expenses 1,682 64
Acquisition costs           43  
Income before finance costs and income taxes     1,922       3,696  
Finance costs
Interest expense, net 2,132 1,137
Amortization of transaction costs     137       143  
      2,269       1,280  
(Loss) income before income taxes     (347 )     2,416  
 
Income tax (recovery) expense
Current 32 843
Deferred     (56 )     (190 )
      (24 )     653  
Net (loss) income for the period     (323 )     1,763  
 
Basic and diluted (loss) earnings per share (0.02 ) 0.09
Weighted average number of common shares outstanding, basic and
diluted
21,523,515 20,039,159
 
 
As at March 31, 2019 and December 31, 2018

As at Mar. 31,
2019 (1)

Advertisement
Stake.com

As at Dec. 31,
2018

(in thousands of Canadian dollars, unaudited)     $     $
Current assets 85,810 85,455
Current liabilities 72,756 64,716
 
Total assets 202,879 142,231
Total non-current liabilities 123,013 70,003
 
Shareholders’ equity     7,110       7,512  
(1)     2019 results include the impact of the adoption of new accounting
standard IFRS 16. Refer to note 3 of the condensed interim
consolidated financial statements for the three months ended March
31, 2019 and related management’s discussion & analysis for further
details of the impact of the adoption of new accounting standards.
 

Table 2 The following table provides reconciliations of
net (loss) income to EBITDA and of net (loss) income to Adjusted EBITDA
for the periods noted. See “Non-IFRS Measures”.
       

EBITDA and Adjusted EBITDA Reconciliation

             
For the periods ended March 31, 2019 and 2018 January 1 to March 31, 2019

January 1 to
March 31, 2018

(in thousands of Canadian dollars, unaudited)        
     

Proforma
without IFRS 16
adjustment

Advertisement
Stake.com
   

IFRS 16
adjustments

    As reported     As reported
Net (loss) income for the period (1)     $ 178       $ (501 )     $ (323 )     $ 1,763  
       
Interest expense, net (1) 1,231 901 2,132 1,137
Amortization of transaction costs 137 137 143
Current income tax expense 32 32 843
Deferred income tax recovery (56 ) (56 ) (190 )
Depreciation of property, plant and equipment 1,119 1,119 1,148
Amortization of intangible assets 647 647 1,069
Depreciation of ROU Asset (1)           2,077       2,077        
EBITDA $ 3,288 $ 2,477 $ 5,765 $ 5,913
 
Restructuring expenses 1,682 1,682 64
One-time business reorganization costs (2) 412 412 332
Acquisition costs                       43  
Adjusted EBITDA     $ 5,382       $ 2,477       $ 7,859       $ 6,352  
(1)     2019 results include the impact of the adoption of new accounting
standard IFRS 16. Refer to note 3 of the condensed interim
consolidated financial statements for the three months ended March
31, 2019 and related management’s discussion & analysis for further
details of the impact of the adoption of new accounting standards.
 
(2) One-time business reorganization costs include non-recurring
headcount reduction expenses for employees that did not qualify as
restructuring costs.
 

Table 3 The following table provides reconciliations of
net (loss) income to Adjusted net income and a presentation of Adjusted
net income per share for the periods noted. See “Non-IFRS Measures”.
         

Adjusted Net Income Reconciliation

               
For the periods ended March 31, 2019 and 2018 January 1 to March 31, 2019

January 1 to
March 31, 2018

(in thousands of Canadian dollars, except share and per share
amounts, unaudited)
         
       

Proforma
without IFRS 16
adjustment

Advertisement
Stake.com
   

IFRS 16
adjustments

    As reported     As reported
Net (loss) income for the period (1)       $ 178       $ (501 )     $ (323 )     $ 1,763  
       
Restructuring expenses 1,682 1,682 64
One-time business reorganization costs (2) 412 412 332
Acquisition costs 43
Tax effect of the above adjustments       (546 )           (546 )     (103 )
Adjusted net income       $ 1,726       $ (501 )     $ 1,225       $ 2,099  
 
Adjusted net income per share, basic and diluted       $ 0.08       $ (0.02 )     $ 0.06       $ 0.09  
Weighted average number of common shares outstanding, basic and
diluted
      21,523,515     21,523,515     21,523,515     20,039,159
Number of common shares outstanding, basic and diluted       21,523,515     21,523,515     21,523,515     20,039,159
(1)     2019 results include the impact of the adoption of new accounting
standard IFRS 16. Refer to note 3 of the condensed interim
consolidated financial statements for the three months ended March
31, 2019 and related management’s discussion & analysis for further
details of the impact of the adoption of new accounting standards.
 
(2) One-time business reorganization costs include non-recurring
headcount reduction expenses for employees that did not qualify as
restructuring costs.
 

Revenues
For the three months ended March 31, 2019,
DCM recorded revenues of $78.5 million, a decrease of $10.0 million or
11.3% compared with the same period in 2018. The first quarter of 2018
included significantly higher volume than normal from one particular
customer, by approximately $4.9 million compared to this year. The
decrease in relative revenues for the three months ended March 31, 2019
was also due to (i) the loss of a lower margin customer, (ii) the timing
of orders, (iii) some softness in spend from certain customers, and (iv)
certain non-recurring work. The decrease was partially offset by (i) an
increase in revenues from new customers in the Cannabis industry, (ii)
year over year growth from a large customer in the financial services
industry which was onboarded in late 2017, (iii) gains in wallet share
from existing customers with new applications and (iv) the acquisition
of Perennial which was not reflected in the comparative period as the
acquisition was completed in the second quarter of 2018.

Cost of Revenues and Gross Profit
For the three
months ended March 31, 2019, cost of revenues decreased to $57.8 million
from $67.0 million for the same period in 2018, resulting in a $9.2
million or 13.8% decrease over the same period last year. Excluding the
effects of adopting IFRS 16, cost of revenues for the three months ended
March 31, 2019 was $58.1 million.

Gross profit for the three months ended March 31, 2019 was
$20.8 million, which represented a decrease of $0.7 million or 3.3% from
$21.5 million for the same period in 2018. Gross profit as a percentage
of revenues increased to 26.4% for the three months ended March 31,
2019, compared to 24.3% for the same period in 2018. Excluding the
effects of adopting IFRS 16, gross profit for the three months ended
March 31, 2019 was $20.4 million or 26.0% as a percentage of revenues.
The increase in gross profit as a percentage of revenues for the three
months ended March 31, 2019 was positively impacted by (i) higher
margins attributed to the acquisition of Perennial which was not
reflected in the comparative period, (ii) continued refinement of DCM’s
pricing discipline, (iii) cost reductions realized from prior cost
savings initiatives, and (iv) improvements in product mix compared to
last year. The increase in gross profit as a percentage of revenues was,
however, partially offset by the impact of paper and other raw materials
price increases leading to somewhat compressed margins on contracts with
certain existing customers.

Selling, General and Administrative Expenses (“SG&A”)
SG&A
expenses for the three months ended March 31, 2019 decreased
$0.5 million or 2.9% to $17.2 million, or 21.8% of total revenues,
compared to $17.7 million, or 20.0% of total revenues, for the same
period of 2018. After deducting one-time business reorganization costs,
SG&A expenses were $16.8 million, or 21.3% of total revenues compared to
$17.4 million or 19.7% of revenues in the prior period. The decrease in
SG&A expenses for the three months ended March 31, 2019 was primarily
attributable to (i) benefits from the cost saving initiatives
implemented in the last two quarters of 2018, and (ii) reduction of
amortization expense of intangible assets that were fully amortized in
the fourth quarter of 2018. The decrease was partially offset by an
increase in SG&A from the acquisition of Perennial which was not
reflected in the comparative period, and an increase in non-recurring
headcount reduction expenses for employees that did not qualify as
restructuring costs.

Advertisement
Stake.com

Restructuring Expenses
Cost reductions and
enhancement of operating efficiencies have been an area of focus for DCM
over the past four years in order to improve margins and better align
costs with the declining revenues experienced by the Company in its
traditional business, a trend being faced by the traditional printing
industry for several years now.

For the three months ended March 31, 2019, DCM incurred restructuring
expenses of $1.7 million compared to $0.1 million in the same period in
2018. In 2019, the restructuring costs related to (i) headcount
reductions due to the closure of the Brossard, Quebec facility, and (ii)
headcount reductions to direct and indirect labour from various
facilities across DCM as cost savings initiatives to improve gross
margin.

DCM will continue to evaluate its operating costs for further
efficiencies as part of its commitment to improving its gross margins
and lowering its selling, general and administration expenses.

Adjusted EBITDA
For the three months ended March 31,
2019, Adjusted EBITDA increased by $1.5 million to $7.9 million, or
10.0% of revenues, after adjusting EBITDA for the $1.7 million in
restructuring charges and $0.4 million of one-time business
reorganization costs. The adoption of IFRS 16 resulted in a higher
Adjusted EBITDA for the first quarter of 2019 due to changes in the
recognition and classification of lease payments from cost of sales and
SG&A expenses to depreciation of $2.1 million and interest expense of
$0.9 million, respectively. Excluding the effects of adopting IFRS 16,
Adjusted EBITDA for the three months ended March 31, 2019 was $5.4
million, or 6.9% of revenues. The decrease of $1.0 million in Adjusted
EBITDA for the three months ended March 31, 2019 over the same period
last year excluding IFRS 16 was attributable to a decrease in revenues,
with a corresponding decrease in gross profit. The decline was offset
due to the acquisition of Perennial which was not reflected in the
comparative period, and a reduction in SG&A.

Interest Expense
Interest expense including interest
on debt outstanding under DCM’s credit facilities, interest accretion
expense related to certain debt obligations recorded at fair value, and
interest expense on lease liabilities under IFRS 16 was $2.1 million for
the three months ended March 31, 2019 compared to $1.1 million for the
same period in 2018. Excluding the effects of adopting IFRS 16, interest
expense for the three months ended March 31, 2019 was $1.2 million.
Interest expense for the three months ended March 31, 2019 was
relatively consistent with the same period in the prior year excluding
IFRS 16. The slight increase was primarily due to the Crown facility,
secured in 2018 to fund the acquisition of Perennial and repay the
outstanding balance on its subordinated debt facility with Bridging
Financing Inc. (“Bridging Credit Facility”), which was not reflected in
the comparative period as the facility was obtained in the second
quarter of 2018. The increase was offset by a reduction in the unwinding
of discount which was included in interest expense of the Eclipse and
Thistle VTBs that were repaid during the current period.

Advertisement
Stake.com

Income Taxes
DCM reported a loss before income taxes
of $0.3 million and a net income tax recovery of $24 thousand for the
three months ended March 31, 2019 compared to income before income taxes
of $2.4 million and a net income tax expense of $0.7 million for the
three months ended March 31, 2018. The decrease in the current income
tax expense to a recovery position was due to the reduction of DCM’s
estimated taxable income for the three months ended March 31, 2019. The
deferred income tax recovery for the three months ended March 31, 2019
primarily relates to changes in estimates of future reversals of
temporary differences.

Net Loss
Net loss for the three months ended March
31, 2019 was $0.3 million compared to a net income of $1.8 million for
the same period in 2018. Excluding the effects of adopting IFRS 16, net
income for the three months ended March 31, 2019 was $0.2 million. The
decrease in comparable profitability for the three months ended March
31, 2019 was primarily due to (i) the decrease in revenues, with a
corresponding decline in the gross profit, and (ii) an increase in
restructuring expenses. This decrease was partially offset by (i)
continued implementation of the refined discipline in DCM’s pricing
strategy resulting in an increase in gross margin as a percentage of
revenues, (ii) cost benefits as a result of the restructuring efforts
implemented in the last two quarters of 2018, and (iii) a reduction in
SG&A expense.

Adjusted Net Income
Adjusted net income for the three
months ended March 31, 2019 was $1.2 million compared to Adjusted net
income of $2.1 million for the same period in 2018. The adoption of IFRS
16 resulted in a lower Adjusted net income for the first quarter of 2019
by $0.5 million due to changes in net income as discussed in Table 1.
Excluding the effects of adopting IFRS16, Adjusted net income for the
three months ended March 31, 2019 was $1.7 million. The decrease in
comparable profitability for the three months ended March 31, 2019 was
primarily due to the decrease in revenues, with a corresponding decline
in the gross margin. This decrease was partially offset by (i) continued
implementation of the refined discipline in DCM’s pricing strategy
resulting in an increase in the gross margin as a percentage of
revenues, (ii) cost benefits as a result of the restructuring efforts
implemented in the last two quarters of 2018, and (iii) a reduction in
SG&A expense.

CASH FLOW FROM OPERATIONS
During the three months ended
March 31, 2019, cash flows generated by operating activities were $10.1
million compared to cash flows generated by operating activities of $6.1
million during the same period in 2018. Current period cash flow from
operations, after adjusting for non-cash items, generated a total of
$6.7 million compared with $5.5 million for the same period last year.
As a result of the adoption of IFRS 16, $2.5 million in lease payments
are now presented as cash used for financing activities in the condensed
interim consolidated statement of cash flow for the period ended March
31, 2019. In the prior year comparative period, this was classified as a
reduction of operating activities thereby contributing to the variance
in cash flow from operations year over year. In addition, current period
cash flows from operations were negatively impacted by the decrease in
revenues however this was slightly offset by an improvement in gross
margin and a decline in SG&A expenses.

Changes in working capital during the three months ended March 31, 2019
generated $6.0 million in cash compared with $3.7 million of cash
generated in the prior year. $6.8 million of the increase in current
period working capital was primarily a result of DCM’s continued efforts
to better align the timing of payments to its suppliers with collections
on outstanding receivables from its customers. This was slightly offset
by higher volumes in inventory purchases thereby reducing working
capital by $1.2 million.

Advertisement
Stake.com

Lastly, there were lower payments for severances and lease termination
payments related to DCM’s restructuring initiatives totaling $1.4
million during the current period compared with $2.2 million for the
same period last year.

INVESTING ACTIVITIES
For the three months ended March 31,
2019, $2.3 million in cash flows were used for investing activities
compared with $1.4 million during the same period in 2018. In the
current period, $0.5 million of cash was primarily used to invest in IT
equipment and costs related to leasehold improvements to set up
production equipment compared with $0.

Contacts

Mr. Gregory J. Cochrane
Chief Executive Officer
DATA
Communications Management Corp.
Tel: (905) 791-3151

Mr. James E. Lorimer
Chief Financial Officer
DATA
Communications Management Corp.
Tel: (905) 791-3151
ir@datacm.com

Advertisement
Stake.com

Read full story here


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Innocan

Innocan Pharma Submits Investigational New Animal Drug Application to FDA’s Veterinary Center

Published

on

innocan-pharma-submits-investigational-new-animal-drug-application-to-fda’s-veterinary-center

HERZLIYA, Israel and CALGARY, AB, July 26, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA’s Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver and assigned an Investigational New Animal Drug (INAD) number for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product. This represents a significant step for the Company, as an INAD designation facilitates correspondence and data exchange with CVM to support LPT-CBD development as a new veterinary drug.

 

 

The Company further announced that following the assessment of LPT-CBD’s scientific package, the CVM recognized Innocan’s contribution to pursuing innovative animal drug products and technology and granted the company a sponsor fee waiver for fiscal year 2024.  

Innocan’s LPT-CBD is a proprietary drug delivery platform designed to provide prolonged-release CBD for chronic pain and well-being management in animals. Over the past year, repeated administration of LPT-CBD in dogs and other animals has demonstrated both efficacy and tolerability, providing sufficient evidence for the INAD application.

Advertisement
Stake.com

“We are thrilled by CVM’s response,” said Prof. Chezy Barenholz, CSO of Innocan Pharma. “The granted INAD will allow us to advance the investigational studies of LPT-CBD and share knowledge to support future discussions with CVM on LPT-CBD’s development plan. Moreover, the fee waiver, granted by CVM, supports our development and pursuit of innovative animal drug products and technology, further validating our approach and potential impact in veterinary medicine.”

Dr. Eyal Kalo, R&D Director at Innocan, added, “LPT-CBD is a unique technology that has proven itself worthy of the INAD fee waiver granted by CVM. This will streamline our efforts to deliver a unique solution for chronic pain management to the animal market.”

About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/

Contact Information:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com 

Advertisement
Stake.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Advertisement
Stake.com

Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-submits-investigational-new-animal-drug-application-to-fdas-veterinary-center-302207435.html

Continue Reading

Cannabis

Verano Announces the Opening of Zen Leaf Fairless Hills, the Company’s Newest Affiliated Dispensary in Pennsylvania, in Prime New Location

Published

on

  • Zen Leaf Fairless Hills, the Company’s newest affiliated dispensary in Pennsylvania, relocated from its former home in Chester to 203 Lincoln Highway, a busy thoroughfare with daily traffic of over 17,000 vehicles per day1
  • As the first medical cannabis dispensary in the city, Zen Leaf Fairless Hills will offer an elevated experience for area patients, including increased convenience and accessibility with numerous point-of-sale stations and kiosks for seamless in-store browsing and ordering
  • Verano’s active operations span 13 states, comprised of 142 dispensaries and 13 cultivation and processing facilities with more than 1 million square feet of cultivation capacity

CHICAGO, July 26, 2024 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the opening of Zen Leaf Fairless Hills in Pennsylvania on Friday, July 26th, following a ceremonial ribbon cutting at 11 a.m. local time. Zen Leaf Fairless Hills is located at 203 Lincoln Highway and will be open Monday through Saturday from 9 a.m. to 8 p.m. and Sunday from 10 a.m. to 6 p.m. local time.

The dispensary is located in Bucks County, the fourth largest county in the Commonwealth with a total population of over 630,0002 residents. To increase accessibility and convenience, Zen Leaf Fairless Hills features large in-store kiosks and numerous point-of-sale stations to enhance the browsing and ordering experience for patients. To celebrate the grand opening of Zen Leaf Fairless Hills and following a ceremonial ribbon cutting, patients will be greeted with complimentary deals and doorbusters on featured branded products.

“We are excited to bring the Zen Leaf experience to local patients in Fairless Hills, where our talented team members will continue to deliver hospitality-driven care and top-quality products for local patients,” said George Archos, Verano Founder and Chief Executive Officer. “As the Pennsylvania medical cannabis patient population continues to grow, we are grateful for the opportunity to deepen our roots in Bucks County at our newest Zen Leaf location in the Commonwealth, and look forward to providing a warm and welcoming environment for current and future patients.”

Zen Leaf Fairless Hills adds another convenient outlet for Philadelphia area patients, and solidifies Verano’s footprint in the state as one of the Company’s 18 affiliated Pennsylvania dispensaries. Verano’s Pennsylvania operations also include a state-of-the-art 62,000 square foot cultivation and processing facility in Chester, where the Company produces its signature Verano Reserve flower and Troches, concentrates and vapes; (the) Essence and Savvy flower and extracts; and Avexia RSO cannabis oil and topicals. For additional convenience and accessibility, patients can choose to order ahead at ZenLeafDispensaries.com for express in-store pickup.

About Verano

Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF), one of the U.S. cannabis industry’s leading companies based on historical revenue, geographic scope and brand performance, is a vertically integrated, multi-state operator embracing a mission of saying Yes to plant progress and the bold exploration of cannabis. Verano provides a superior cannabis shopping experience in medical and adult use markets under the Zen Leaf and MÜV dispensary banners, including Cabbage Club, an innovative annual membership program offering exclusive benefits for cannabis consumers. Verano produces a comprehensive suite of high-quality, regulated cannabis products sold under its diverse portfolio of trusted consumer brands including Verano, (the) Essence, MÜV, Savvy, BITS, Encore, and Avexia. Verano’s active operations span 13 U.S. states, comprised of 13 production facilities with over 1,000,000 square feet of cultivation capacity. Learn more at Verano.com.

Advertisement
Stake.com

Contacts:

Media
Verano
Steve Mazeika
VP, Communications
Steve.Mazeika@verano.com

Investors
Verano
Julianna Paterra, CFA
VP, Investor Relations
Julianna.Paterra@verano.com

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans, strategies, or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “future”, “scheduled”, “estimates”, “forecasts”, “projects,” “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein, including, without limitation, the risk factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, its quarterly report on Form 10-Q for the quarter ended March 31, 2024 and any subsequent quarterly reports on Form 10-Q, in each case, filed with the U.S. Securities and Exchange Commission at www.sec.gov. The Company makes no assurances and cannot predict the outcome of all or any part of the on-going litigation with Goodness Growth referenced in this press release, including whether the Company will prevail on its Notice of Application and its counterclaim, or whether Goodness Growth will prevail on its claim for damages against the Company. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.

Advertisement
Stake.com

###


1 Pennsylvania Department of Transportation
2 United States Census Bureau

Continue Reading

Cannabis

Unlocking New Horizons in Health: TNR, The Niche Research Reveals the Transformative Power of Minor Cannabinoids

Published

on

Wilmington, Delaware, July 25, 2024 (GLOBE NEWSWIRE) — Minor cannabinoids refer to the lesser-known compounds found in the cannabis plant, distinct from the well-known THC (tetrahydrocannabinol) and CBD (cannabidiol). While THC and CBD dominate the market, minor cannabinoids such as CBG (cannabigerol), CBC (cannabichromene), and CBN (cannabinol) are gaining attention for their potential therapeutic benefits. These compounds are extracted from both marijuana and hemp plants, with varying legal restrictions depending on their THC content. The minor cannabinoids market is poised for significant growth, driven by increasing consumer awareness and demand for alternative health and wellness products. As regulatory environments around cannabis products evolve, companies are exploring the potential of minor cannabinoids in various applications, including pharmaceuticals, nutraceuticals, cosmetics, and food and beverages.

Minor cannabinoids are being researched for their potential therapeutic effects, including anti-inflammatory, analgesic, and neuroprotective properties. This versatility facilitates product diversification in various industries. Companies are investing in research and development to create novel formulations and delivery methods for minor cannabinoids. This includes nano-emulsions, encapsulation technologies, and controlled-release systems to enhance bioavailability and efficacy. For example, in January 2022, CBDA + CBGA Tincture a new product was launched by Hometown Hero CBD. This 30ml tincture contains 600mg each of CBGA, CBDA, CBG, and CBD. Derived from hemp, the cannabinoids in this tincture comply with legal requirements across all 50 states in the USA. There is an increasing consumer preference for natural as well as plant-based remedies, which in turn is driving the demand for cannabinoid-infused products. This trend is particularly strong among younger demographics seeking alternatives to traditional pharmaceuticals. Evolving regulatory frameworks, particularly in regions like North America and Europe, are creating opportunities for legal market expansion. Regulatory clarity is crucial for market participants to navigate compliance and market entry.

Global Minor Cannabinoids Market: Key Datapoints
 

Market Value in 2023

Advertisement
Stake.com
 

US$ 17.8 Bn

 

Market Value Forecast by 2034

 
Advertisement
Stake.com

US$ 42.3 Bn

 

Growth Rate

 

 
Advertisement
Stake.com

8.2%

 

Historical Data

 

 
Advertisement
Stake.com

2016 – 2022

 

Base Year

 

 
Advertisement
Stake.com

2023

 

Forecast Data

 

 
Advertisement
Stake.com

2024 – 2034

Increasing consumer interest in health and wellness products, coupled with the perceived therapeutic benefits of cannabinoids, is a major driver of market growth. Progressive cannabis legalization in various parts of the world, including the United States and parts of Europe, is expanding the addressable market for minor cannabinoids. Significant investments in research and development by pharmaceutical and biotechnology companies are accelerating product innovation and clinical trials. The market remains fragmented with opportunities for new entrants and niche players to introduce specialized products catering to specific consumer needs.

Get Sample Copy of the Report

The COVID-19 pandemic initially disrupted supply chains and retail channels for minor cannabinoids products. However, the crisis also underscored the importance of health and wellness, leading to increased interest in natural remedies, including cannabinoids. As economies recover, the market is expected to rebound stronger.

The geopolitical tensions, such as the Russia-Ukraine conflict, have also affected global markets, including the minor cannabinoids sector. Fluctuating currency values, supply chain disruptions, and geopolitical uncertainty have impacted production and distribution channels. However, the long-term impact will depend on geopolitical developments and their influence on global trade and regulatory environments.

Advertisement
Stake.com

The minor cannabinoids market presents significant opportunities for growth and innovation, driven by evolving consumer preferences, regulatory advancements, and expanding research initiatives. Companies that can navigate regulatory complexities, invest in research and development, and respond to shifting consumer trends are well-positioned to capitalize on this emerging market. As the market matures, collaboration across sectors and regions will be crucial in unlocking the full potential of minor cannabinoids in various industries worldwide.

Visit our Homepage

Global Minor Cannabinoids Market: Key Takeaways of the Report

  • Cannabigerol (CBG) segment by product type is expected to grow at a CAGR of 6.7% in the minor cannabinoids market due to increasing research highlighting its potential therapeutic benefits, including anti-inflammatory, antimicrobial, and neuroprotective properties. As consumer awareness grows and regulatory environments become more favorable, there is heightened interest in CBG-based products for their diverse health applications, ranging from skincare to pharmaceutical formulations, driving sustained market demand and expansion.
  • Pharmaceutical segment by application, leads the minor cannabinoids market with a significant revenue share of 35.8% owing to growing recognition of cannabinoids’ potential in therapeutic applications. Cannabinoids like CBD, CBG, and others show promise in treating conditions such as epilepsy, chronic pain, and anxiety disorders, backed by increasing clinical research and favorable regulatory developments. Pharmaceutical companies are investing heavily in cannabinoid-based drug development, driving market growth as they seek to capitalize on these compounds’ efficacy and market potential in addressing unmet medical needs.
  • In 2023, Latin America is anticipated as fastest growing region in the global minor cannabinoids market due to evolving regulatory landscapes favoring cannabis legalization and cultivation. This shift is fostering a burgeoning industry infrastructure for cannabis extraction and product development. Additionally, increasing consumer acceptance of cannabinoid-based products for medicinal and wellness purposes is driving market expansion. With a vast potential consumer base and supportive regulatory frameworks, Latin America presents significant growth opportunities for companies seeking to enter or expand within the minor cannabinoids market.

Key Development:

  • In December 2023, Rare Cannabinoid Company introduced Uplift Gummies infused with THC and THCV. These gummies combine the relaxing properties of Delta-9-THC with the energizing and appetite-controlling effects of CBD and THCV.
  • In October 2022, High Tide Inc., a cannabis retailer, announced that its Colorado-based subsidiary, NuLeaf Naturals, had launched plant-based softgels and full-spectrum multicannabinoid oil in Manitoba. The products feature CBC, CBD, CBG, Delta-9 tetrahydrocannabinol (Delta 9), and CBN.

Browse Related Category Reports

Global Minor Cannabinoids Market:

  • Aurora Europe GmbH
  • BulKanna
  • CBD. INC.
  • Fresh Bros Hemp Company
  • GCM Holdings, LLC (Global Cannabinoids)
  • GenCanna.
  • High Purity Natural Products.
  • Laurelcrest
  • Mile High Labs
  • PBG Global
  • Rhizo Sciences
  • ZERO POINT EXTRACTION, LLC
  • Other Industry Participants

Global Minor Cannabinoids Market

By Product Type

Advertisement
Stake.com
  • Cannabigerol (CBG)
  • Cannabichromene (CBC)
  • Cannabinol (CBN)
  • Cannabidivarin (CBDV)
  • Tetrahydrocannabutol (THCB)
  • Tetrahydrocannabivarin (THCV)
  • Tetrahydrocannabiphorol (THCP)
  • Others

By Application

  • Pharmaceutical
    • Pain Management
    • Mental Health
    • Sleep Disorders
    • Anti-inflammatory
    • Others
  • Nutraceuticals
  • Cosmetics and Personal Care
  • Food and Beverages
  • Others

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)  

Consult with Our Expert:

Jay Reynolds

The Niche Research

Japan (Toll-Free): +81 663-386-8111

South Korea (Toll-Free): +82-808- 703-126

Saudi Arabia (Toll-Free): +966 800-850-1643

Advertisement
Stake.com

United Kingdom: +44 753-710-5080

United States: +1 302-232-5106

Email: askanexpert@thenicheresearch.com

Website: www.thenicheresearch.com

Advertisement
Stake.com
Continue Reading
Advertisement
Stake.com

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: sales@hipther.agency

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania